Internal Medicine, Endocrinology, Diabetes, & Metabolism · Brooklyn, NY
NPI
1043593940
Since 2011
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
2952 Brighton 3rd St, #401
Brooklyn, NY, 11235
Phone (718) 975-3833
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.1M
20,361 services
Medicare patients, 2024
1,540
Average age 76
Drug cost, 2024
$7.3M
18,457 prescriptions
Company payments, 2025
$4,095
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Iraklii Buziashvili was code 99490 (chronic, principal, and transitional care management), 3,492 times for 581 patients. In total Iraklii Buziashvili billed 20,361 services in 34 codes, and Medicare paid $1.1M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-06-24.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99490 Chronic, Principal, and Transitional Care Management | Office | 3,492 | 581 | $55.04 | $192K |
| 99232 Hospital E&M - Subsequent | Facility | 3,361 | 419 | $69.86 | $235K |
| 99454 E&M - Miscellaneous | Office | 2,099 | 200 | $44.43 | $93K |
| 99214 Office E&M - Established | Office | 1,986 | 805 | $112.46 | $223K |
| 82962 Clinical Chemistry | Office | 1,298 | 606 | $3.21 | $4,167 |
| J0897 Injection, denosumab, 1 mg | Office | 1,260 | 18 | $21.13 | $27K |
| 99233 Hospital E&M - Subsequent | Facility | 1,192 | 122 | $104.81 | $125K |
| 36415 Venipuncture Blood Collection | Office | 950 | 527 | $8.63 | $8,200 |
| 99222 Hospital E&M - Initial | Facility | 503 | 435 | $116.53 | $59K |
| 99457 E&M - Miscellaneous | Office | 457 | 146 | $43.64 | $20K |
| 95251 Test - Miscellaneous | Office | 220 | 131 | $30.22 | $6,648 |
| 99309 SNF E&M | Facility | 179 | 36 | $94.98 | $17K |
| 99204 Office E&M - New | Office | 170 | 170 | $147.81 | $25K |
| 99223 Hospital E&M - Initial | Facility | 155 | 124 | $153.14 | $24K |
| 96401 Chemotherapy Administration | Office | 104 | 65 | $66.64 | $6,930 |
By year: 2022 $1.1M for 16,882 services; 2023 $1.3M for 19,461 services; 2024 $1.1M for 20,361 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 1,298 | 606 | $3.21 | $4,167 |
| 36415 Venipuncture Blood Collection | 950 | 527 | $8.63 | $8,200 |
Medicare prescription drug claims, 2024
In 2024, the drug Iraklii Buziashvili prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 1,704 prescriptions and refills. In total Iraklii Buziashvili wrote 18,457 Medicare prescriptions that cost $7.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 1,704 | 1,812 | 305 | $1.8M |
| Atorvastatin Calcium Generic | 1,593 | 2,406 | 420 | $8,422 |
| Trulicity Dulaglutide | 1,227 | 1,414 | 257 | $1.3M |
| Synjardy Xr Empagliflozin/Metformin Hcl | 1,022 | 1,311 | 196 | $739K |
| Jardiance Empagliflozin | 919 | 1,151 | 198 | $662K |
| Levothyroxine Sodium Generic | 856 | 1,219 | 175 | $4,773 |
| Metformin Hcl Generic | 851 | 1,140 | 195 | $3,287 |
| Ozempic Semaglutide | 778 | 857 | 172 | $795K |
| Rosuvastatin Calcium Generic | 753 | 995 | 178 | $5,708 |
| Metformin Hcl Er Metformin Hcl | 502 | 696 | 122 | $5,280 |
| Losartan Potassium Generic | 462 | 748 | 117 | $2,941 |
| Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp | 348 | 510 | 82 | $80K |
| Humulin R U-500 Kwikpen Insulin Regular, Human | 347 | 410 | 53 | $255K |
| Glimepiride Generic | 306 | 378 | 61 | $1,055 |
| Metoprolol Succinate Generic | 299 | 437 | 74 | $2,585 |
Brand drugs: 9,050 claims; generic drugs: 8,010 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Iraklii Buziashvili $4,095 ($4,095 in general payments such as food, travel and fees) from 9 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $3,225.
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $3,225 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 7 | $197 |
| Lilly USA, LLC LLY | 7 | $185 |
| Amgen Inc. AMGN | 7 | $142 |
| Madrigal Pharmaceuticals MDGL | 4 | $136 |
| Xeris Pharmaceuticals, Inc. | 4 | $86.37 |
| Abbvie Inc. ABBV | 3 | $74.97 |
| Novo Nordisk Inc NVO | 1 | $26.04 |
| Antares Pharma, Inc. | 1 | $23.63 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.